MedTrace Logo

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

NCT06537999 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-04-30

No results posted yet for this study

Summary

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of Claseprubart (DNTH103) in participants with multifocal motor neuropathy (MMN).

Conditions

  • Multifocal Motor Neuropathy

Interventions

DRUG

Claseprubart

* Day 1: IV loading dose * Week 1 to Week 15: Claseprubart administered SC every 2 weeks

DRUG

Placebo

* Day 1: IV infusion of placebo * Week 1 to Week 15: placebo administered SC every 2 weeks

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-17
Primary Completion
2026-06-30
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States
  • Denmark
  • France
  • Italy
  • Netherlands
  • North Macedonia
  • Poland
  • Serbia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06537999 on ClinicalTrials.gov